TICKERNERD
Menu
SANASANAHealthcare · Biotechnology

SANA Stock Forecast: Sana Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.13
+1.29% on the day

The 9 Wall Street analysts covering Sana Biotechnology, Inc. hold a median 12-month price target of $7 — +123.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$937.0M
Ticker Nerd rank
31 / 100
Median analyst target
$7.00
Analysts covering
9
Revenue$0.0
Operating income−$65.4M
Net income−$63.6M
Free cash flow−$34.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−20.2%
1M
−17.4%
YTD
−23.1%
1Y
−7.9%
From 52W high
−47.1%
From 52W low
+16.8%
$2.68
$5.92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SANA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sana Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
82
Issuance
57
Growth
54
Size
45
Momentum
44
Value
41
Revisions
30
Quality
21
Volatility
17

Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (17): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SANA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SANA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26SANAHigh $12.00Median $7.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $6.00Median $7.00High $12.00

The green dot is the last close — the median target sits +123.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Aug 2026B of A SecuritiesMaintainsBuy$7.00 → $6.00
14 Apr 2026WedbushMaintainsOutperform$6.00 → $7.00
14 Apr 2026WedbushMaintainsOutperform—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
6 Jan 2026B of A SecuritiesMaintainsBuy—
7 Nov 2025HC Wainwright & Co.MaintainsBuy—
7 Nov 2025WedbushMaintainsOutperform—
30 Oct 2025CitizensMaintainsMarket Outperform—
24 Sept 2025WedbushInitiatesOutperform—
3 July 2025Morgan StanleyAssumesOverweight$12
24 June 2025JMP SecuritiesReiteratesMarket Outperform—
24 Apr 2025HC Wainwright & Co.ReiteratesBuy—
18 Mar 2025Citizens Capital MarketsUpgradeMarket Outperform—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy—
14 Mar 2025JefferiesInitiatesBuy—
8 Jan 2025HC Wainwright & Co.MaintainsBuy—
8 Jan 2025TD CowenUpgradeBuy—
27 Nov 2024HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024HC Wainwright & Co.ReiteratesBuy—
5 Nov 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SANA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SANA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Sana Biotechnology, Inc. returned −7.9% against +17.5% for the S&P 500, dividends included.

SANA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26SANAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SANA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Sana Biotechnology, Inc. (SANA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.3×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
6.1×

Cheaper than 16% of US stocks

EV / EBITDA
−4.9×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−152.9%

Higher than 9% of US stocks

Return on assets
−29.2%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sana Biotechnology, Inc. (SANA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sana Biotechnology, Inc. has a market value of $937.0M and an enterprise value of $857.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$211.8M.

  • Diluted earnings per share, trailing twelve months: $−0.76.

  • Free cash flow in the twelve months to 30 June 2026: −$135.1M.

  • Shares outstanding: 299.3M.

  • Trailing P/E: −3.3×; forward P/E: −5.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Sana Biotechnology, Inc. employs 142 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

SANA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SANASana Biotechnology, Inc.$937.0M
31
SGPSpyGlass Pharma, Inc.$916.9M
2
SLDBSolid Biosciences, Inc.$914.6M
43
FTHFaeth Therapeutics, Inc.$965.2M
55
DSGNDesign Therapeutics, Inc.$902.3M
65
OLMAOlema Pharmaceuticals, Inc.$890.7M
30
LXRXLexicon Pharmaceuticals, Inc.$889.9M
68

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sana Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SANA news & analysis

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

Sana Biotechnology, Inc. presented a transcript of its appearance at Citigroup's Biopharma Back to School Summit 2026, as published by Seeking Alpha. The excerpt provides only the headline and source information with no additional details.

Why it matters — A SANA watcher would care because investor presentations at major conferences like Citigroup's summit can provide insight into the company's business strategy and pipeline updates.

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

Sana Biotechnology, Inc. presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of its presentation made available on Seeking Alpha. The item reports on the company's conference participation.

Why it matters — SANA watchers can follow the company's remarks and updates shared during its presentation at a major industry healthcare conference.

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 7 Sept 2026negative

A legal firm is reaching out to Sana Biotechnology, Inc. shareholders, encouraging them to contact the firm to discuss their rights and options regarding a potential breach of fiduciary duties by company insiders. The firm notes it would handle any matter on a contingent fee basis, with no out-of-pocket legal costs for shareholders.

Why it matters — SANA watchers would care because the news signals a potential shareholder legal action alleging that company insiders may have breached fiduciary duties.

Sana Biotechnology to Present at September 2026 Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Sana Biotechnology announced it will webcast presentations featuring a business overview and update at four investor conferences in September 2026. The presentations will be held in September.

Why it matters — The webcast presentations offer Sana watchers an opportunity to hear the company's latest business update and overview at multiple investor conferences.

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 29 July 2026negative

A law firm is contacting Sana Biotechnology shareholders regarding potential breaches of fiduciary duties by company insiders, offering to handle matters on a contingent fee basis.

Why it matters — This alerts SANA watchers to possible legal challenges against the company's leadership that could impact governance and shareholder value.

FAQ

Frequently asked questions about SANA stock

What is the SANA stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Sana Biotechnology, Inc. have a median 12-month price target of $7, with estimates ranging from $6 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SANA stock a buy right now?

Of the 9 analysts covering Sana Biotechnology, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sana Biotechnology, Inc. 31 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SANA?

As at 12 Sept 2026, Sana Biotechnology, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).

Will SANA stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +123.6% from the last close, and Ticker Nerd's factor model ranks Sana Biotechnology, Inc. 31 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SANA stock forecast for 2030?

No analyst covering Sana Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SANA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $12 over the next 12 months.

How has SANA stock performed over the past year?

Sana Biotechnology, Inc. returned -7.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sana Biotechnology, Inc. do?

Sana Biotechnology Inc. is a biotechnology company focused on creating and delivering engineered cells as medicines.

What is the latest news on SANA?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". Sana Biotechnology, Inc. presented a transcript of its appearance at Citigroup's Biopharma Back to School Summit 2026, as published by Seeking Alpha. The excerpt provides only the headline and source information with no additional details.

Company

About Sana Biotechnology, Inc.

Sana Biotechnology Inc. is a biotechnology company focused on creating and delivering engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms designed to address serious diseases with unmet treatment needs, including type 1 diabetes, B cell-mediated autoimmune diseases, oncology, and other immune-related conditions. Its work centers on modifying, replacing, or repairing cells to support next-generation therapeutic approaches, with research and development spanning cell therapy, gene delivery, and immune evasion technologies. Sana Biotechnology operates as a clinical-stage company and does not yet market approved commercial therapies, making its role in the market primarily centered on innovation, pipeline development, and translational research. Headquartered in Seattle, Washington, the company is part of the broader biotechnology sector, where engineered-cell platforms are an important area of active drug development.

CEO Dr. Steven D. Harr M.D. · 142 employees · United States · https://www.sana.com